ReviewCNS drugs2011
Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.
Review in CNS drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 478 citations in OpenAlex.
- Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use.Nature genetics · 2019Pooled it
- Sex and Chronic Stress Alter the Distribution of Corticotropin-Releasing Factor Receptor in Rat Hippocampus Following Oxycodone Conditioned Place Preference.Synapse (New York, N.Y.) · 2026Article
- The Role of Oxytocin and Oxytocin Gene Receptor Methylation During Withdrawal Therapy in Males With Alcohol Use Disorder.Addiction biology · 2025Article
- Rapid nongenomic estrogen signaling controls alcohol drinking behavior in mice.Nature communications · 2024Article
- Recent Advances in Pyrimidine-Based Drugs.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Novel RNA-Seq Signatures Post-Methamphetamine and Oxycodone Use in a Model of HIV-Associated Neurocognitive Disorders.Viruses · 2023Article
- Sex-differences in anxiety, neuroinflammatory markers, and enhanced fear learning following chronic heroin withdrawal.Psychopharmacology · 2023Article
- Neurodevelopmental origins of substance use disorders: Evidence from animal models of early-life adversity and addiction.The European journal of neuroscience · 2022Review
- Linking the gut microbiome to microglial activation in opioid use disorder.Frontiers in neuroscience · 2022Review
- Oxytocin Signaling as a Target to Block Social Defeat-Induced Increases in Drug Abuse Reward.International journal of molecular sciences · 2021Review
- Pituitary adenylate cyclase-activating polypeptide (PACAP) modulates dependence-induced alcohol drinking and anxiety-like behavior in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Medications Development for Treatment of Opioid Use Disorder.Cold Spring Harbor perspectives in medicine · 2021Review
- Social interaction reward in rats has anti-stress effects.Addiction biology · 2021Article
- Involvement of cAMP-Dependent Protein Kinase in the Nucleus Accumbens in Cocaine Versus Social Interaction Reward.International journal of molecular sciences · 2020Article
- Article
- Neuropeptide and cytokine regulation of pain in the context of substance use disorders.Neuropharmacology · 2020Review
- Expression and Distribution of Neuropeptide-Expressing Cells Throughout the Rodent Paraventricular Nucleus of the Thalamus.Frontiers in behavioral neuroscience · 2020Review
- Role of BNST CRFR1 Receptors in Incubation of Fentanyl Seeking.Frontiers in behavioral neuroscience · 2020Article
- Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Signaling and the Dark Side of Addiction.Journal of molecular neuroscience : MN · 2019Review
- CRF modulation of central monoaminergic function: Implications for sex differences in alcohol drinking and anxiety.Alcohol (Fayetteville, N.Y.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Drug dependence is a chronically relapsing disorder that places an enormous strain on healthcare systems. For treatments to have long-term clinical value, they must address the causes of relapse. Corticotropin-releasing factor (CRF), a neuropeptide central to the stress response, may be one key to solving the relapse cycle. CRF is hypothesized to mediate the elevated anxiety and negative emotional states experienced during the development of dependence. This review summarizes existing data on changes in the CRF system produced by drugs of abuse and the function of CRF receptors in regulating behavioural responses to drugs of abuse, with an emphasis on drug dependence. Drug-induced changes in neuronal excitability throughout the limbic system, as well as the reversal of these neuroadaptations by CRF receptor antagonists, are also addressed. CRF receptor antagonists, by reducing the motivational effects of drug withdrawal and protracted abstinence, are proposed to be novel therapeutic targets for drug abuse and addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.